Pipeline

We are building a deep and compelling pipeline of product candidates with the potential to advance care and outcomes for patients with diverse autoimmune or inflammatory diseases

  • Discovery /Pre-clinical
  • Phase I
  • Phase II
  • PIVOTAL OR PHASE III

NEXT ANTICIPATED MILESTONE

Rademikibart
(CBP-201)

Antibody targeting IL-4Rα cytokine receptor
(Th2 cell modulator)

Atopic Dermatitis (AD) - China
Atopic Dermatitis (AD) - Global
Asthma - Global
  •  
  •  
  •  
  •  
  • Pivotal trial Stage 2 readout in Q4’23 & NDA by end of Q1’24
  • Seeking partnership to advance Global Ph3
  • Topline readout in Q4’23

Icanbelimod
(CBP-307)

Small molecule targeting S1P1 (Th1 cell modulator)

Ulcerative Colitis
  •  
  •  
  •  
  •  
Crohn's Disease
  •  
  •  
  •  
  •  
  • Maintenance data reported Q2’2023
  • Seeking partnerships to advance into future trials for both indications

CBP-174

Small molecule (target undisclosed)

Pruritis
  •  
  •  
  •  
  •  
  • First-in-Man completed

CBP-233

IL-33 mAb

Type 2 Inflammatory Diseases
  •  
  •  
  •  
  •  
  • To initiate IND-enabling studies in H1 2024

CBP-246

Antibody targeting IL-1RAcP

Type 2 Inflammatory Diseases
  •  
  •  
  •  
  •  
  • To initiate IND-enabling studies in 2H 2023

CBP-403

Bispecific mAb targeting Th2 cytokines

  •  
  •  
  •  
  •  
Type 2 Inflammatory Diseases
  • Development candidate nomination in 2H 2023
Don't delete this section - it contains the styling for the pipeline bars, but is invisible to visitors